• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Merck's Price Strength Is Ailing

Even if the stock bounces, an advance is unlikely.
By BRUCE KAMICH
Oct 30, 2017 | 12:25 PM EDT
Stocks quotes in this article: MRK

Merck (MRK) was confined to a sideways trading range from February, but recently broke to the downside. Selling has been pretty intense with two gaps to the downside and heavy volume.

I looked at MRK at the end of June: "I like buying strength because it tells me I am trading with the market's direction. I would suggest that traders go long MRK on strength above $67 and risk a close below $63 or approximately where the 200-day moving average line intersects."

I must admit I did not anticipate the rapid breakdown in prices recently, but I am glad I dodged a bullet by not getting long MRK, as it never rallied above $67. Not much of a consolation. Let's check the current charts and indicators to see if it might be a time to buy the break.

In this updated daily bar chart of MRK, above, we can see the sideways consolidation pattern between $61 on the downside and short of $67 on the upside. Prices crossed above and below the 50-day and 200-day moving average lines several times, but prices started a downward path in mid-September. Prices made a peak in September that equaled the June peak, but the On-Balance-Volume (OBV) line made a slightly lower peak. This bearish divergence began to play out quicker as MRK moved into October.

The OBV line picked up speed on the downside, signaling that sellers of MRK were being more aggressive with heavier trading volume on days when the stock closed lower. The Moving Average Convergence Divergence (MACD) oscillator crossed to the downside for a take-profits sell signal.

More bearish signals have been triggered recently with the slope of the 50-day moving average line going negative and the MACD oscillator crossing below the zero line.

In this weekly bar chart of MRK, above, we can see prices have rapidly broken below the rising 40-week moving average line. The chart shows some support around $58 but not so much to feel confident that the area will hold. The weekly OBV line has been making lower highs since February and the weekly MACD oscillator has crossed below the zero line for an outright sell signal on this timeframe.

In this Point and Figure chart of MRK, above, we can see the sharp decline without the price gaps. The trade at $56 broke support at $57 and opened the way for a possible deeper decline to the $44 area, according to this method of charting.

Bottom line: Prices have made a sharp decline in a short period of time, so they are extended on the downside (a.k.a. oversold). Prices could bounce, but without a base pattern or new accumulation, a sustained advance is unlikely at this time. The Point and Figure chart suggests risk down to $44, but support can be seen beginning around $51.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login